MedElevator
Войти в исследования International journal of rheumatic diseases · 2026
Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein as Treatment for Gout Flare.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luo Jiao, Xie Zhongming, Zhang Weizhong, Liu Sijia, Duan Lihua
Аннотация
OBJECTIVES: A single-center, prospective, random, open-label study of acute gout patients treated with etanercept.
METHODS: The treatment protocol involved subcutaneous administration of etanercept at a dose of 25 mg twice in five days. The control group received 20 mg of methylprednisolone administered intravenously every day for a total of five days. Baseline assessments, conducted at the initiation of etanercept included visual analogue scale (VAS) scores and C-reactive protein (CRP) levels. The levels of CRP and VAS in the gout patient after being injected with etanercept or methylprednisolone for 5 days. Adverse events were diligently recorded throughout the study period.
RESULTS: Etanercept demonstrated rapid and substantial alleviation of pain and inflammatory responses in all 12 acute gout patients. Its effect is comparable to that of methylprednisolone.
CONCLUSION: Etanercept might be contemplated for "off-label" use in gout patients who do not respond to standard therapy or glucocorticoid therapy, encounter severe side-effects and contraindications.
METHODS: The treatment protocol involved subcutaneous administration of etanercept at a dose of 25 mg twice in five days. The control group received 20 mg of methylprednisolone administered intravenously every day for a total of five days. Baseline assessments, conducted at the initiation of etanercept included visual analogue scale (VAS) scores and C-reactive protein (CRP) levels. The levels of CRP and VAS in the gout patient after being injected with etanercept or methylprednisolone for 5 days. Adverse events were diligently recorded throughout the study period.
RESULTS: Etanercept demonstrated rapid and substantial alleviation of pain and inflammatory responses in all 12 acute gout patients. Its effect is comparable to that of methylprednisolone.
CONCLUSION: Etanercept might be contemplated for "off-label" use in gout patients who do not respond to standard therapy or glucocorticoid therapy, encounter severe side-effects and contraindications.